


ISSN 2313-7347 (print)

ISSN 2500-3194 (online)

# АКУШЕРСТВО ГИНЕКОЛОГИЯ РЕПРОДУКЦИЯ

Включен в перечень ведущих  
рецензируемых журналов и изданий ВАК

2025 • том 19 • № 3



OBSTETRICS, GYNECOLOGY AND REPRODUCTION

2025 Vol. 19 No 3

<https://gynecology.su>

Данная интернет-версия статьи была скачана с сайта <http://www.gynecology.su>. Не предназначено для использования в коммерческих целях. Информацию о репринтах можно получить в редакции. Тел.: +7 (495) 649-54-95; эл. почта: [info@info1.ru](mailto:info@info1.ru).



# Sechenov University Professors Grigorios Gerotziafas and Ismail Elalamy have been elected as foreign members of the Russian Academy of Sciences

**Профессора Сеченовского Университета Григориос Геротзиафас и Исмаил Элалами избраны иностранными членами Российской академии наук**

On May 29–30, 2025, General meeting of members of the Russian Academy of Sciences elected foreign members of the Russian Academy of Sciences among which are members of the editorial board of the “Obstetrics, Gynecology and Reproduction” Journal Professor Grigoris Gerotziafas (France) and Professor Ismail Elalamy (Morocco).

## Professor Grigorios Gerotziafas

Professor Grigoris Gerotziafas was born in Thessaloniki, Greece, in 1967. He received his Medical Doctor (MD) degree from the Faculty of Medicine, Aristotle University of Thessaloniki in 1992. He subsequently earned a PhD in Cardiovascular Pharmacology from Pierre et Marie Curie University (Paris VI) in 1999 and became a board-certified specialist in Hematology in 2002. In 2016, he was awarded the Habilitation à Diriger la Recherche (HDR) by the Faculty of Medicine, Sorbonne University, Paris.

He is Director of the Research Department Cancer, Vessels, Biology, and Therapeutics (CaVITE) and Head of the Cancer, Angiogenesis, Thrombosis and Haemostasis group at the Centre de Recherche Saint-Antoine (CRSA), INSERM UMRS\_938, Faculty of Medicine, Sorbonne University. He also leads the postgraduate Master's program Thrombosis, Haemostasis, Diagnosis and Therapy (DU T2H) at Sorbonne University (Fig. 1).

An internationally recognized expert in thrombosis and haemostasis, Professor Gerotziafas specializes in cancer-associated thrombosis, antithrombotic therapy, vascular complications during pregnancy, and vascular-related causes of subfertility and assisted reproductive failure.

He established and developed the Thrombosis Center at Tenon–Saint Antoine University Hospital in Paris, which includes a highly specialized Hemostasis Laboratory integrated with an active clinical network. This center provides care for hospitalized patients and operates an outpatient clinic for individuals with coagulation disorders requiring personalized treatment strategies. He notably pioneered the development of specialized Consultations in Thrombosis in Oncology and in Obstetrics.

Appointed as a Foreign Member of the Russian Academy of Sciences, Professor Gerotziafas holds Affiliate

Professor positions at the Department of Molecular Pharmacology and Therapeutics, Center for Translational Research and Education, Faculty of Medicine, Loyola University Chicago, USA.

Professor Gerotziafas leads several international fundamental, translational, and clinical research projects, including:

- ASTERIX – a fundamental research project investigating the procoagulant fingerprint of cancer cells and the protective role of fibrin clot “shields” in resistance to targeted and cellular anticancer therapies;
- COMPASS-CAT – a clinical research project focused on developing and implementing AI-driven models for risk assessment of cancer-associated thrombosis;
- ROADMAP – a translational research initiative evaluating clinically relevant biomarkers of hypercoagulability and endothelial activation for risk stratification in cancer-



Figure 1. Professor Grigorios Gerotziafas.

Рисунок 1. Профессор Григориос Геротзиафас.

associated thrombosis, in vitro fertilization failure, pre-eclampsia, long COVID-19, resistance to anticancer therapies;

- THALOS – an applied research project dedicated to the development of electronic decision support tools in thrombosis and haemostasis.

During the COVID-19 pandemic, on behalf of the VAS European Foundation on Angiology and Vascular Medicine, he coordinated two major international initiatives: the Project for Guidance on the Management of Vascular Patients with COVID-19 and the International Group for an Integrated and Equitable Strategy Against the COVID-19 Pandemic. He has contributed as an expert to numerous national and international clinical guidelines on the prevention and treatment of venous thromboembolism and arterial thrombosis.

Professor Gerotziafas holds leadership roles in several prominent scientific organizations, including International Society on Thrombosis and Haemostasis (ISTH) – Scientific and Standardization Committee on Haemostasis and Malignancy; Committee for Control of Anticoagulation; European Hematology Association (EHA) – Specialized Working Group on Bleeding and Thrombosis; International Conference on Thrombosis and Haemostasis Issues in Cancer (ICTHIC); European Thrombosis and Haemostasis Alliance (ETHA); VAS – Vascular Independent Research and Education European Organization – Chair of the Scientific Committee; European and Mediterranean League Against Thromboembolic Disease (EMLTD) – Member of the Board of Trustees.

He has published extensively in leading international peer-reviewed journals, authored multiple books and book chapters, and serves on the editorial boards of several high-impact scientific journals.

Professor Gerotziafas is also deeply committed to the support, advancement and sustainability of national public health systems. His academic affiliations at Sorbonne University (France), Sechenov University (Russia), and Loyola University (USA) along with a broad academic network in Greece and Cyprus, support the development of a robust international collaborative ecosystem dedicated to thrombosis and haemostasis. These transnational partnerships foster multidisciplinary research and clinical innovation, particularly in the domains of health and emerging technologies. His global academic engagement strengthens the collective capacity to address complex vascular disorders through integrative strategies and equitable knowledge exchange across institutions and borders.

### Professor Ismail Elalamy

Professor Ismail Elalamy was born in Marrakesh (Morocco), in 1958. He is MD, PhD, Professor of Hematology. Previously Director of the Hematology Department at Tenon University Hospital (Sorbonne University) in Paris (2007–2023), he currently holds the

positions of Dean of the Private Faculty of Medicine in Marrakech (FONDATION UPM des Sciences de la Santé, Morocco) and consultant in Hematology Thrombosis and Hemostasis at the American Hospital of Paris (France).

Professor Elalamy has been involved in the field of thrombosis & hemostasis and antithrombotic therapies since 1988, and his research interests include improving therapeutic strategies, identifying new biomarkers and the application of novel diagnosis techniques to the clinic. He did his fundamental research into the links between inflammation, coagulation and platelet aggregation being a Postdoc Fellow at the Pasteur Institute (Paris) from 1998–2003 and Associate Professor of Hematology at Hotel-Dieu (Paris, Assistance Publique-Hôpitaux de Paris) from 1998–2008. He is actively involved in the Research Group on Hemostasis and Thrombosis in Cancer (INSERM UMR S-938, Sorbonne University). In his position, Professor Elalamy has established a reference center for diagnosis and management of heparin-induced thrombocytopenia, and an expert center for thrombotic or bleeding risk stratification (cancer, pregnancy or assisted reproduction therapy, familial thrombophilia, etc.) with specialized clinical and laboratory activity in platelet studies (Fig. 2).

Professor Elalamy holds positions as Past-President of the French Society of Angiology, President of ARTER (Association for Research on Thrombosis and Evaluation of its Risk), Councillor of EMLTD (Euro-Mediterranean League against Thromboembolic Diseases), as well as President of GITA (Interdisciplinary Group on Antithrombotic Treatments) and co-chair of the ISTH subcommittee on Control of Anticoagulation (International Society on Thrombosis and Haemostasis) and Member of ETHA (European Thrombosis and Haemostasis Alliance).

He contributed to the redaction of several national and international recommendations and standards such as, in 2020, the First Expert Consensus Statement for Prevention and Treatment of Venous Thromboembolism Associated with COVID-19 Infection with Chinese experts, a Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19 (VAS-European Independent Foundation in Angiology/Vascular Medicine) and, in 2021, Clinical Practice Guidelines on the Management of Venous Thromboembolism (European Society for Vascular Surgery, ESVS) or, in 2022, Guidelines for Thromboprophylaxis and Treatment of Cancer-Associated Thrombosis (Multinational Association of Supportive Care in Cancer, MASCC) and French Association of Oncological Supportive Care (AFSOS) and lastly, EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer. Recently, Professor Elalamy has established a Think Tank called AHOPE, Alliance for Hemostasis Optimization with Pluridisciplinary Expertise in Africa. It aims to bring together experts from various fields, to collaborate on improving care for hemostasis disorders, ensuring

a comprehensive, innovative and integrated approach to their management in all multiple contexts.

Since 1998, Professor Elalamy has given over 300 symposia and plenary lectures at international congresses, on a diverse range of issues including platelet activation, heparin-induced thrombocytopenia, hereditary thrombophilia, antithrombotic strategies and resistance to anti-platelet agents. He has written over 230 peer reviewed articles and collaborated on several books on hemostasis and thrombosis, as well as editing the first French language book on heparin-induced thrombocytopenia and a practical guidebook on direct oral anticoagulants.

Professor Grigorios Gerotziafas and Professor Ismail Elalamy, elected as foreign members of the Russian Academy of Sciences, are students of one of the world's most famous pioneers in the field of clinical hemostasis, Professor Meyer-Michel Samama from the Sorbonne University. Meyer-Michel Samama is the teacher of Academician of the Russian Academy of Sciences, Professor A.D. Makatsariya, with whom he maintained contacts for 40 years. Communicating with Professor Samama at early stage of his career largely determined the scientific direction that A.D. Makatsariya has been currently pursuing.

Both Professor Grigorios Gerotziafas and Professor Ismail Elalamy have been actively participating in conferences and scientific events held under the auspices of the Russian Academy of Sciences over the past three years. Also, G. Gerotziafas and I. Elalamy have held a position of professor for several years at the Department of Obstetrics, Gynecology and Perinatal Medicine headed by Dr. A.D. Makatsariya at the Filatov Clinical Institute of Children's Health, Sechenov First Moscow State Medical



**Figure 2.** Professor Ismail Elalamy.

**Рисунок 2.** Профессор Исмаил Элалами.

University of the Ministry of Health of the Russian Federation (Sechenov University), participating in all of its scientific and educational projects.

In particular, Professor Grigorios Gerotziafas and Professor Ismail Elalamy have been actively collaborating with Viktoria Omarovna Bitsadze (Dr Sci Med) and Jamilya Khizrievna Khizroeva (Dr Sci Med), both Professors of the Department, aimed at scientific research of vital problems, which combines the knowledge, technology and experience of researchers from different countries.